

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NALOX-1 PHARMACEUTICALS, LLC,

Petitioner

v.

ADAPT PHARMA OPERATIONS LIMITED, AND

OPIANT PHARMACEUTICALS, INC.,

Patent Owners

IPR2019-00694

U.S. Patent No. 9,629,965

SUPPLEMENTAL DECLARATION OF MAUREEN DONOVAN, Ph.D.

TABLE OF CONTENTS

I.	OVERVIEW	1
II.	MY BACKGROUND AND QUALIFICATIONS	6
III.	LEGAL STANDARDS	7
IV.	BASIS OF MY ANALYSIS WITH RESPECT TO OBVIOUSNESS.....	8
	A. Wyse would not have directed a Formulator POSA away from using benzalkonium chloride in an intranasal naloxone formulation.	8
	1. A Formulator POSA would have concluded that naloxone degradants in Wyse’s formulations could not have been caused by BAC.	8
	2. A Formulator POSA would not know from Wyse’s prototyping studies that any one ingredient was the cause of naloxone degradation.....	15
	B. None of the other prior art cited by Dr. Jones would have directed a Formulator POSA away from using BAC in an intranasal naloxone formulation.	18
	C. A Formulator POSA would have been highly motivated to use BAC as the preservative in an intranasal naloxone formulation.....	21
	D. The claimed naloxone formulation does not have “unexpected” stability – a Formulator POSA would have been expected the claimed formulation to be stable.	23
V.	CONCLUSION.....	24

***Inter Partes Review of U.S. Patent No. 9,629,965
Supplemental Declaration of Maureen Donovan, Ph.D. (Nalox1201)***

I, Maureen D. Donovan, Ph.D., do hereby declare as follows:

I. OVERVIEW

1. I am over the age of 18 and otherwise competent to make this Declaration. This Declaration is based on my personal knowledge as an expert in the field of pharmaceutical formulation, in particular intranasal formulation. I understand that this Declaration is being submitted in support of Petitioner Nalox-1 Pharmaceuticals, LLC's ("Nalox-1") Reply to Patent Owners' Response to the petition for *Inter Partes* Review ("IPR") of certain claims of U.S. Patent No. 9,629,965 ("the '965 patent") (Nalox1001).

2. This is my second Declaration in this proceeding. Previously, I submitted a Declaration (Nalox1002) in support of Nalox-1's petition for IPR challenging the '965 patent. I refer to that Declaration hereinafter as "my first Declaration."

3. I have now been asked to supplement the opinions I expressed in my first Declaration. I have also been asked to respond to certain opinions contained in the Declaration of Stuart A. Jones, Ph.D. (Ex-2201) and the Declarations of Kenneth A. Williams, M.D. (Ex-2001 and Ex-2202).

4. In preparing this Declaration, I have reviewed the '965 patent and its file history. I have also considered each of the documents listed in the table below, in addition to the exhibits disclosed in my first Declaration. *See* Nalox1002, ¶5.

***Inter Partes Review of U.S. Patent No. 9,629,965
Supplemental Declaration of Maureen Donovan, Ph.D. (Nalox1201)***

Exhibit No.	Description
Nalox1001	U.S. Patent No. 9,629,965 (the '965 patent)
Nalox1002	Expert Declaration of Maureen Donovan (my first Declaration)
Nalox1007	U.S. Patent No. 9,192,570 (Wyse)
Nalox1010	Djupesland, P., <i>Nasal Drug Delivery Device: Characteristics and Performance in a Clinical Perspective – A Review</i> , 3 Drug Deliv. & Transl. Res. 42–62 (2013) (Djupesland)
Nalox1012	Handbook of Pharmaceutical Excipients (Rowe, R. et al. eds., 6th ed. 2009) (HPE)
Nalox1015	U.S. Patent No. 8,198,291 (the '291 patent)
Nalox1022	Bitter, C. et al., <i>Nasal Drug Delivery in Humans</i> , 40 Curr. Probl. Dermatol. 20–35 (2011) (Bitter)
Nalox1028	FDA, Center for Drug Evaluation and Research, <i>Guidance for Industry, Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products – Chemistry, Manufacturing, and Controls Documentation</i> (2002) (2002 FDA Guidance)
Nalox1031	Glende, O., <i>Development of non-injectable naloxone for pre-hospital reversal of opioid overdose: A Norwegian project and a review of international status</i> (May 2016) (unpublished M.A. thesis, Norwegian University of Science and Technology) (on file with Norwegian University of Science and Technology) (Glende)
Nalox1044	Physicians' Desk Reference, <i>NARCAN [Naloxone Hydrochloride Injection, USP], IMITREX Nasal Spray [Sumatriptan]</i> , 1300–02, 1546–50 (57th ed., 2003) (PDR 2003)
Nalox1206	Bureš, F., <i>Quaternary Ammonium Compounds: Simple in Structure, Complex in Application</i> , 377(14) Topics in Current Chemistry (2019) (Bureš)

*Inter Partes Review of U.S. Patent No. 9,629,965
Supplemental Declaration of Maureen Donovan, Ph.D. (Nalox1201)*

Exhibit No.	Description
Nalox1208	Connors, K. et al., <i>Oxidation and Photolysis, in Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists</i> 82–114 (2d ed. 1986) (Connors)
Nalox1210	Ehrick, J. et al., <i>Considerations for the Development of Nasal Dosage Forms, in Sterile Product Development: Formulation, Process, Quality and Regulatory Considerations</i> 99–144 (Parag Kolhe, et al., eds., 2013) (Ehrick)
Nalox1213	FDA, Center for Drug Evaluation and Research, Guidance for Industry, <i>Q8(R2) Pharmaceutical Development</i> (Revision 2 2009) (2009 FDA Guidance)
Nalox1214	Hiom, S., <i>Preservation of Medicines and Cosmetics, in Principles and Practice of Disinfection, Preservation & Sterilization</i> 484–514 (Fraise, A.P. et al., eds., 4th ed. 2004) (Hiom)
Nalox1218	Hsu, H. et al., <i>Effect of Formulation Variables on the Nasal Permeability and Stability of Naloxone Intranasal Formulations</i> , 20(232) AAPS PharmaSciTech (2019) (Hsu)
Nalox1219	<i>Inactive Ingredient Search for Approved Drug Products, Search Names Beginning with B</i> , U.S. FDA (Mar. 3, 2020, 12:08 PM), https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm?event=browseByLetter.page&Letter=B (FDA B Names)
Nalox1220	<i>Inactive Ingredient Search for Approved Drug Products: Frequently Asked Questions</i> , U.S. FDA (Mar. 3, 2020, 12:12 PM), https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredient-search-approved-drug-products-frequently-asked-questions (FDA FAQ)
Nalox1227	Marx, D. et al., <i>Intranasal Drug Administration – An Attractive Delivery Route for Some Drugs</i> , InTech Open (2015) (Marx)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.